Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, November 19, 2018
Abzena has augmented existing 500 L scale biologics equipment with 20m$ of investment into two new manufacturing suites at 500 L and 2000 L scale in a new GMP facility in San Diego.
read more
Wednesday, April 14, 2021
Abzena has announced that the location of its new GMP manufacturing facility will be Sanford, North Carolina.
read more
Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site.
read more
Wednesday, January 13, 2021
Abzena has announced the addition of a 6th Global site that will augment cGMP manufacturing capacity for mammalian biologics.
read more
Wednesday, December 23, 2020
Abzena has appointed Kimball Hall, Chief Operating Officer at Abzena as President in addition to her COO role.
read more
Wednesday, September 19, 2018
Abzena has signed an agreement with Tmunity Therapeutics, a clinical stage T cell therapy company in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies.
read more
Wednesday, August 19, 2020
Abzena has announced the appointment of Anu Bansal as Senior Director of Manufacturing at its facility in Bristol, Pennsylvania.
read more
Abzena has announced the appointment of Matthew LeClair as Senior Vice President (SVP) and Site Head of its San Diego Operations.
read more
Abzena has completed a technology transfer and scalability evaluation using the Synaffix technologies of GlycoConnect™ (antibody conjugation) and HydraSpace™ (highly polar spacer).
read more
Thursday, February 27, 2025
Abzena announced that Taylor Boyd has joined the company as its Chief Business Officer (“CBO”). In this newly created role, Boyd will be responsible for corporate development, portfolio strategy, and partnering strategy activities that drive Abzena’...
read more
Abzena announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately. Mr. Glass has served as Chairman of the Board since 2022.
read more
Abzena has appointed Dr. Campbell Bunce as Chief Scientific Officer (CSO) and Bo Adair MBA as Senior Vice President Process and Operations.
read more
Tuesday, January 25, 2022
Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Jim Kennamer as Senior Vice President and Site Head of North Carolina.
read more
Tuesday, February 01, 2022
Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Kevin Lundquist as Chief Financial Officer, effective January 31, 2022...
read more
Abzena, the leading end-to-end integrated CDMO for complex biologic molecules and Antibody Drug Conjugates (ADCs) has announced the appointment of Thomas Castellano, as Chief Financial Officer.
read more